AMABILE, MARILINA
AMABILE, MARILINA
DIPARTIMENTO DI EMATOLOGIA E SCIENZE ONCOLOGICHE "L. e A. SERAGNOLI"
M. Amabile; AMABILE M
Identifying patient subgroups with different trends of patient-reported outcomes (PROMs) after elective knee arthroplasty
2023 Golinelli D.; Grassi A.; Sanmarchi F.; Tedesco D.; Esposito F.; Rosa S.; Rucci P.; Amabile M.; Cosentino M.; Bordini B.; Fantini M.P.; Zaffagnini S.
Patient-reported outcomes in patients undergoing elective arthroplasty: the PaRIS-IOR study
2020 Golinelli, D; Rosa, S; Rucci, P; Tedesco, D; Grassi, A; Amabile, M; Cosentino, M; Maietti, E; Zaffagnini, S; Fantini, M P
Patient-reported outcome measures (PROMs) after elective hip, knee and shoulder arthroplasty: Protocol for a prospective cohort study
2019 Grassi A.; Golinelli D.; Tedesco D.; Rolli M.; Bordini B.; Amabile M.; Rucci P.; Fantini M.P.; Zaffagnini S.
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors
2014 Ilaria Iacobucci, Annalisa Lonetti, Emanuela Ottaviani, Daniela Cilloni, Francesca Messa, Stefania Paolini, Cristina Papayannidis, Pier Paolo Piccaluga, Panagiota Giannoulia, Simona Soverini, Marilina Amabile, Giuseppe Saglio, Fabrizio Pane, Giorgio Berton, Anna Baruzzi, Antonella Vitale, Robin Foa, Michele Baccarani, Giovanni Martinelli
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.
2011 Gugliotta G.; Castagnetti F.; Palandri F.; Breccia M.; Intermesoli T.; Capucci A.; Martino B.; Pregno P.; Rupoli S.; Ferrero D.; Gherlinzoni F.; Montefusco E.; Bocchia M.; Tiribelli M.; Pierri I.; Grifoni F.; Marzocchi G.; Amabile M.; Testoni N.; Martinelli G.; Alimena G.; Pane F.; Saglio G.; Baccarani M.; Rosti G.
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients.
2011 Durante, S; Terragna, C; Astolfi, A; Palandri, F; Castagnetti, F; Testoni, N; Amabile, M; Iacobucci, I; Soverini, S; Alimena, G; Breccia, M; Pane, F; Saglio, G; Rosti, G; Baccarani, M; Martinelli, G
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.
2011 Marzocchi G.; Castagnetti F.; Luatti S.; Baldazzi C.; Stacchini M.; Gugliotta G.; Amabile M.; Specchia G.; Sessarego M.; Giussani U.; Valori L.; Discepoli G.; Montaldi A.; Santoro A.; Bonaldi L.; Giudici G.; Cianciulli A.M.; Giacobbi F.; Palandri F.; Pane F.; Saglio G.; Martinelli G.; Baccarani M.; Rosti G.; Testoni N.
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis
2010 Castagnetti F; Testoni N;Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A;Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience
2010 Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandra; Lonetti, Annalisa; Ferrari, Anna; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Clissa, Cristina; Parisi, Sarah; Guadagnuolo, Viviana; Baccarani, Michele; Martinelli, Giovanni
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
2010 Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP.
2009 Testoni N; Marzocchi G; Luatti S; Amabile M; Baldazzi C; Stacchini M; Nanni M; Rege-Cambrin G; Giugliano E; Giussani U; Abruzzese E; Kerim S; Grimoldi MG; Gozzetti A; Crescenzi B; Carcassi C; Bernasconi P; Cuneo A; Albano F; Fugazza G; Zaccaria A; Martinelli G; Pane F; Rosti G; Baccarani M.
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience
2009 Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandra; Lonetti, Annalisa; Baldazzi, Carmen; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Castagnetti, Fausto; Poerio, Angela; Clissa, Cristina; Parisi, Sarah; Polverelli, Nicola; Guadagnuolo, Viviana; Pier Paolo Piccaluga, ; Rosti, Gianantonio; Baccarani, Michele; Martinelli, Giovanni
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION
2009 Colarossi, S.; Gnani, A.; Soverini, S.; Castagnetti, F.; Marzocchi, G.; Luatti, S.; Astolfi, A.; Formica, S.; Iacobucci, I.; Lonetti, A.; Palandri, F.; Poerio, A.; Amabile, M.; Rosti, G.; Pession, A.; Testoni, N.; Baccarani, M.; Martinelli, G.
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia
2009 Soverini, Simona; Gnani, Alessandra; Colarossi, Sabrina; Vitale, Antonella; Castagnetti, Fausto; Palandri, Francesca; Paolini, Stefania; Papayannidis, Cristina; Amabile, Marilina; Iacobucci, Ilaria; Poerio, Angela; Scotlandi, Katia; Lonetti, Annalisa; Mandelli, Franco; Baccarani, Michele; Foà, Robin; Martinelli, Giovanni
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
2009 Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R.
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
2009 Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party.
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
2009 Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; Rosti G; Baccarani M.
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
2009 Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G.
Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP
2009 Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G.
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate.
2008 Bocchia M; Ippoliti M; Gozzetti A; Abruzzese E; Calabrese S; Amabile M; Pirrotta MT; Crupi R; Tozzuoli D; Trawinska MM; Defina M; Martinelli G; Lauria F.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Identifying patient subgroups with different trends of patient-reported outcomes (PROMs) after elective knee arthroplasty | Golinelli D.; Grassi A.; Sanmarchi F.; Tedesco D.; Esposito F.; Rosa S.; Rucci P.; Amabile M.; Co...sentino M.; Bordini B.; Fantini M.P.; Zaffagnini S. | 2023-01-01 | BMC MUSCULOSKELETAL DISORDERS | - | 1.01 Articolo in rivista | Golinelli_2023.pdf; 12891_2023_6373_MOESM1_ESM.docx |
| Patient-reported outcomes in patients undergoing elective arthroplasty: the PaRIS-IOR study | Golinelli, D; Rosa, S; Rucci, P; Tedesco, D; Grassi, A; Amabile, M; Cosentino, M; Maietti, E; Zaf...fagnini, S; Fantini, M P | 2020-01-01 | EUROPEAN JOURNAL OF PUBLIC HEALTH | - | 4.02 Riassunto (Abstract) | - |
| Patient-reported outcome measures (PROMs) after elective hip, knee and shoulder arthroplasty: Protocol for a prospective cohort study | Grassi A.; Golinelli D.; Tedesco D.; Rolli M.; Bordini B.; Amabile M.; Rucci P.; Fantini M.P.; Za...ffagnini S. | 2019-01-01 | BMC MUSCULOSKELETAL DISORDERS | - | 1.01 Articolo in rivista | s12891-019-2745-3.pdf |
| The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors | Ilaria Iacobucci, Annalisa Lonetti, Emanuela Ottaviani, Daniela Cilloni, Francesca Messa, Stefani...a Paolini, Cristina Papayannidis, Pier Paolo Piccaluga, Panagiota Giannoulia, Simona Soverini, Marilina Amabile, Giuseppe Saglio, Fabrizio Pane, Giorgio Berton, Anna Baruzzi, Antonella Vitale, Robin Foa, Michele Baccarani, Giovanni Martinelli | 2014-01-01 | CANCER RESEARCH | - | 1.06 Abstract in rivista | - |
| Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. | Gugliotta G.; Castagnetti F.; Palandri F.; Breccia M.; Intermesoli T.; Capucci A.; Martino B.; Pr...egno P.; Rupoli S.; Ferrero D.; Gherlinzoni F.; Montefusco E.; Bocchia M.; Tiribelli M.; Pierri I.; Grifoni F.; Marzocchi G.; Amabile M.; Testoni N.; Martinelli G.; Alimena G.; Pane F.; Saglio G.; Baccarani M.; Rosti G. | 2011-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. | Durante, S; Terragna, C; Astolfi, A; Palandri, F; Castagnetti, F; Testoni, N; Amabile, M; Iacobuc...ci, I; Soverini, S; Alimena, G; Breccia, M; Pane, F; Saglio, G; Rosti, G; Baccarani, M; Martinelli, G | 2011-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. | Marzocchi G.; Castagnetti F.; Luatti S.; Baldazzi C.; Stacchini M.; Gugliotta G.; Amabile M.; Spe...cchia G.; Sessarego M.; Giussani U.; Valori L.; Discepoli G.; Montaldi A.; Santoro A.; Bonaldi L.; Giudici G.; Cianciulli A.M.; Giacobbi F.; Palandri F.; Pane F.; Saglio G.; Martinelli G.; Baccarani M.; Rosti G.; Testoni N. | 2011-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis |
Castagnetti F; Testoni N;Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo... A;Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G |
2010-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience | Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandr...a; Lonetti, Annalisa; Ferrari, Anna; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Clissa, Cristina; Parisi, Sarah; Guadagnuolo, Viviana; Baccarani, Michele; Martinelli, Giovanni | 2010-01-01 | CANCER RESEARCH | - | 4.02 Riassunto (Abstract) | - |
| The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. | Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N...; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M | 2010-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. | Testoni N; Marzocchi G; Luatti S; Amabile M; Baldazzi C; Stacchini M; Nanni M; Rege-Cambrin G; Gi...ugliano E; Giussani U; Abruzzese E; Kerim S; Grimoldi MG; Gozzetti A; Crescenzi B; Carcassi C; Bernasconi P; Cuneo A; Albano F; Fugazza G; Zaccaria A; Martinelli G; Pane F; Rosti G; Baccarani M. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience | Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandr...a; Lonetti, Annalisa; Baldazzi, Carmen; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Castagnetti, Fausto; Poerio, Angela; Clissa, Cristina; Parisi, Sarah; Polverelli, Nicola; Guadagnuolo, Viviana; Pier Paolo Piccaluga, ; Rosti, Gianantonio; Baccarani, Michele; Martinelli, Giovanni | 2009-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION | Colarossi, S.; Gnani, A.; Soverini, S.; Castagnetti, F.; Marzocchi, G.; Luatti, S.; Astolfi, A.; ...Formica, S.; Iacobucci, I.; Lonetti, A.; Palandri, F.; Poerio, A.; Amabile, M.; Rosti, G.; Pession, A.; Testoni, N.; Baccarani, M.; Martinelli, G. | 2009-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia | Soverini, Simona; Gnani, Alessandra; Colarossi, Sabrina; Vitale, Antonella; Castagnetti, Fausto; ...Palandri, Francesca; Paolini, Stefania; Papayannidis, Cristina; Amabile, Marilina; Iacobucci, Ilaria; Poerio, Angela; Scotlandi, Katia; Lonetti, Annalisa; Mandelli, Franco; Baccarani, Michele; Foà, Robin; Martinelli, Giovanni | 2009-01-01 | CANCER RESEARCH | - | 4.02 Riassunto (Abstract) | - |
| Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. | Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R;... Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. | Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava ...C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure | Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; ...Rosti G; Baccarani M. | 2009-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. | Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de... Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP | Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Re...ge Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. | Bocchia M; Ippoliti M; Gozzetti A; Abruzzese E; Calabrese S; Amabile M; Pirrotta MT; Crupi R; Toz...zuoli D; Trawinska MM; Defina M; Martinelli G; Lauria F. | 2008-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |